Sanofi
SNY
|
News
|
$46.34
2.09%
620K
|
Health Technology
(0.0% 1d) (-3.8% 1m) (-18.2% 1y) (0.0% 2d) (-1.8% 3d) (-2.9% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 117,221,969,937
http://www.sanofi.com
Sec Filling | Patents | 100409 employees
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
vaccine cardiovascular diabetes diabetic
add to watch list Paper trade email alert is off
Press-releases
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 02:00) - prnewswire.com
TAK | News | $13.255 0.72% 200K
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
MIRM | $23.58 0.04% 55K
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
report million reach treatment market
Sanofi Cuts Jobs in U.S. Vaccines Division as Part of Restructuring
Published: 2024-04-19 (Crawled : 12:00) - biospace.com/
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
sanofi
J&J, Other Q1 Financials Beg the Queston: What Does It Mean to Miss Expectations?
Published: 2024-04-19 (Crawled : 13:00) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
miss
J&J, Other Q1 Financials Beg the Queston: What Does It Mean to Miss Expectati...
Published: 2024-04-19 (Crawled : 14:00) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
miss
Genentech’s ALK Inhibitor First Adjuvant Treatment for ALK-Positive, Early NSCLC
Published: 2024-04-19 (Just crawled : 15:00) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
ABT | News | $107.24 1.87% 2M
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
PRGO | $30.22 0.94% 140K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
first treatment for
Quebec's INESSS recommends BEYFORTUS for the prevention of RSV for all infants 8 months of age and younger(1)
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: -1.81%
H: 0.0%
C: 0.0%
beyfortus for rsv
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
Published: 2024-04-17 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: -1.81%
H: 0.0%
C: 0.0%
biotech
IGM Biosciences Announces Refocusing of Sanofi Collaboration
Published: 2024-04-17 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
IGMS | $7.24 -2.29% 47K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: -13.23%
collaboration sanofi
Prostate Cancer: Advancements in Prevention and Treatment Drive Global Market Growth
Published: 2024-04-17 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
treatment global growth market
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
Published: 2024-04-17 (Crawled : 05:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
sclerosis for potential
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Last 48 Hours Insiders Buying
CLSD | $1.42 7.58% 100K
|
Health Technology
|
14:00
CDZI P 25000 | $2.275 1.11% 74K
|
Utilities
|
14:00
ETST P 39000 | $0.068 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.47 1.4% 6.6K
|
Finance
|
12:30
ADMQ | $0.0532 480K
|
|
10:30
AXR P 2400 | $22.26 0.41% 180
|
Finance
|
21:00
QCRH P 118 | $56.105 1.25% 11K
|
Finance
|
18:01
VUZI P 7500 | $1.245 -1.19% 140K
|
Electronic Technology
|
18:00
RMCF | $3.5501 390
|
Consumer Non-Durables
|
20:10